2367 — Giant Biogene Holding Co Cashflow Statement
0.000.00%
- HK$39.70bn
- HK$35.65bn
- CNY3.52bn
- 97
- 21
- 82
- 79
Annual cashflow statement for Giant Biogene Holding Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 677 | 973 | 973 | 1,178 | 1,745 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | -10.1 | -165 | -28.3 | 31.7 | -52.5 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -28.3 | 4.64 | -275 | -305 | -79.3 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 656 | 834 | 692 | 932 | 1,647 |
Capital Expenditures | -115 | -76.3 | -111 | -153 | -228 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -475 | -445 | 1,674 | -705 | -299 |
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -590 | -521 | 1,563 | -859 | -527 |
Financing Cash Flow Items | -2.16 | -17.5 | -2,619 | -379 | -3.54 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -2.16 | -17.5 | 4,476 | -5,790 | 51.8 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 64.4 | 295 | 6,735 | -5,772 | 1,173 |